Predictive Oncology Inc. (POAI): Price and Financial Metrics

Predictive Oncology Inc. (POAI): $1.23

-0.04 (-3.15%)

POWR Rating

Component Grades













Add POAI to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • Sentiment is the dimension where POAI ranks best; there it ranks ahead of 97.79% of US stocks.
  • The strongest trend for POAI is in Growth, which has been heading up over the past 52 weeks.
  • POAI ranks lowest in Value; there it ranks in the 4th percentile.

POAI Stock Summary

  • POAI's price/sales ratio is 59.12; that's higher than the P/S ratio of 95.6% of US stocks.
  • With a year-over-year growth in debt of -79.88%, Predictive Oncology Inc's debt growth rate surpasses merely 3.68% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for POAI comes in at -59.54% -- higher than that of only 4.67% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Predictive Oncology Inc, a group of peers worth examining would be CTEK, LOCO, ENSV, NES, and CVEO.
  • POAI's SEC filings can be seen here. And to visit Predictive Oncology Inc's official web site, go to

POAI Valuation Summary

  • POAI's price/sales ratio is 49.8; this is 1210.53% higher than that of the median Healthcare stock.
  • Over the past 138 months, POAI's price/sales ratio has gone down 212.7.
  • Over the past 138 months, POAI's EV/EBIT ratio has gone up 0.4.

Below are key valuation metrics over time for POAI.

Stock Date P/S P/B P/E EV/EBIT
POAI 2021-08-31 49.8 1.3 -2.8 -1.1
POAI 2021-08-30 49.8 1.3 -2.8 -1.1
POAI 2021-08-27 50.7 1.3 -2.9 -1.1
POAI 2021-08-26 51.7 1.4 -2.9 -1.2
POAI 2021-08-25 51.2 1.4 -2.9 -1.2
POAI 2021-08-24 51.7 1.4 -2.9 -1.2

POAI Growth Metrics

  • The year over year net cashflow from operations growth rate now stands at -30.55%.
  • Its 5 year net income to common stockholders growth rate is now at -336.63%.
  • The 5 year revenue growth rate now stands at 121.79%.
Over the past 52 months, POAI's revenue has gone up $870,312.

The table below shows POAI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1.405069 -11.06363 -24.79463
2021-03-31 1.237646 -12.60684 -25.79808
2020-12-31 1.252272 -12.25773 -26.43868
2020-09-30 1.305961 -12.74943 -28.66662
2020-06-30 1.3479 -11.40804 -25.93892
2020-03-31 1.451267 -9.656779 -20.91683

POAI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • POAI has a Quality Grade of D, ranking ahead of 9.52% of graded US stocks.
  • POAI's asset turnover comes in at 0.042 -- ranking 162nd of 185 Medical Equipment stocks.
  • INO, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with POAI.

The table below shows POAI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.042 0.637 -7.254
2021-03-31 0.047 0.635 -18.054
2020-12-31 0.055 0.643 58.433
2020-09-30 0.052 0.629 16.113
2020-06-30 0.050 0.616 9.041
2020-03-31 0.052 0.621 9.870

POAI Price Target

For more insight on analysts targets of POAI, see our POAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.50 Average Broker Recommendation 1.5 (Moderate Buy)

POAI Stock Price Chart Interactive Chart >

Price chart for POAI

POAI Price/Volume Stats

Current price $1.23 52-week high $2.30
Prev. close $1.27 52-week low $0.63
Day low $1.23 Volume 44,920
Day high $1.23 Avg. volume 3,215,979
50-day MA $1.14 Dividend yield N/A
200-day MA $1.22 Market Cap 80.45M

Predictive Oncology Inc. (POAI) Company Bio

Predictive Oncology Inc. operates as a biotechnology company. The Company focuses focuses on applying data and artificial intelligence to personalized medicine and drug discovery. Predictive Oncology serves customers worldwide.

POAI Latest News Stream

Event/Time News Detail
Loading, please wait...

POAI Latest Social Stream

Loading social stream, please wait...

View Full POAI Social Stream

Latest POAI News From Around the Web

Below are the latest news stories about Predictive Oncology Inc that investors may wish to consider to help them evaluate POAI as an investment opportunity.

Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements

Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer researchMINNEAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology, an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, launched a website today that emphasizes its role in advancing its mission. The website features information about Predi

Yahoo | October 19, 2021

Thinking about buying stock in Capricor Therapeutics, vTv Therapeutics, Li-Cycle Holdings, Predictive Oncology, or Rewalk Robotics?

NEW YORK , Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, VTVT, LICY, POAI, and RWLK. Full story available on

Benzinga | September 24, 2021

Predictive Oncology Inc. Announces Newest Board Member

MINNEAPOLIS, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors, pursuant to action of the Board effective September 13, 2021.

Intrado Digital Media | September 15, 2021

Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting

MINNEAPOLIS, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021, the stockholders approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of Company common stock from 100,000,000 to 200,000,000, and the amendment became effective on August 17, 2021. The approval

Yahoo | August 18, 2021

Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021, and provided an update on business activities. Q2 2021 Highlights: Net proceeds of $19.4 million from registered direct equity offering, contributing to a cash balance of $44.9 million on June 30, 2021, compared to $3.4 mill

Yahoo | August 11, 2021

Read More 'POAI' Stories Here

POAI Price Returns

1-mo 8.85%
3-mo 4.24%
6-mo 13.89%
1-year 46.95%
3-year -86.63%
5-year -95.90%
YTD 67.94%
2020 -71.94%
2019 -57.90%
2018 -38.61%
2017 -63.93%
2016 -96.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8178 seconds.